David Sinclair/X
May 4, 2026, 17:00
David Sinclair: NMN Modulates Immune Response in Antibody-Mediated Bleeding Disorder
David Sinclair, Author and Host of Lifespan, shared a post on X about a recent article by Huiyuan Li et al., published in Nature, adding:
”New Clinical Trial Result:
NMN suppresses harmful antibody-driven immune attacks to alleviate a common bleeding disorder. Authors suggest it may help other autoimmune diseases like lupus and rheumatoid arthritis.”
Title: Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Authors: Huiyuan Li, Yuan Xu, Yunfei Chen, Lulu Ji, Yanmei Xu, Wenting Zheng, Ting Sun, Rongfeng Fu, Xiaolei Pei, Xiaofan Liu, Feng Xue, Wei Liu, Wentian Wang, Ying Chi, Renchi Yang, Jun Wei, Lei Zhang
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region
-
Jun 26, 2026, 10:11Kayla Kilani: First-Ever CT Perfusion Scan Performed Inside a Mobile Stroke Unit
-
Jun 26, 2026, 07:38Baraa Nassar: High Clinical Suspicion Is Essential for Early Diagnosis of CVST
-
Jun 26, 2026, 07:10Saleh Shamse Basha: Why APTT Alone Can Be Misleading During UFH Monitoring
-
Jun 26, 2026, 06:01Nicolas Hubacz: A Sharper Look at the Brain’s Vascular Landscape
-
Jun 26, 2026, 05:57Ayse Bahar Keleşoğlu Dinçer: New Insights into Antiphospholipid Syndrome Classification and Recurrent Thrombosis Risk